BioStock: SynAct Pharma kicks off 2026 ahead of ADVANCE results
SynAct Pharma enters the new year with a continued focus on the company’s clinical programs and plans for a Capital Markets Day in Q2026 2025 to showcase the opportunities. Following an active end to 2026, which included a new share option program for new executives, a buyback mandate, insider share purchases and lock-up agreements for management and board all ahead of upcoming key results. BioStock reached out to CEO Jeppe Øvlesen to discuss the positioning for this year.
Read the full interview at biostock.se:
SynAct Pharma gears up for 2026 and the ADVANCE results
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/